Abstract
Silymarin and its major constituent, Silibinin, are extracts from the medicinal plant Silybum marianum (milk thistle) and have traditionally been used for the treatment of liver diseases. Recently, these orally active, flavonoid agents have also been shown to exert significant anti-neoplastic effects in a variety of in vitro and in vivo cancer models, including skin, breast, lung, colon, bladder, prostate and kidney carcinomas. The aim of the present review is to examine the pharmacokinetics, mechanisms, effectiveness and adverse effects of silibinins anti-cancer actions reported to date in pre-clinical and clinical trials. The review will also discuss the results of current research efforts seeking to determine the extent to which the effectiveness of silibinin as an adjunct cancer treatment is influenced by such factors as histologic subtype, hormonal status, stromal interactions and drug metabolising gene polymorphisms. The results of these studies may help to more precisely target and dose silibinin therapy to optimise clinical outcomes for oncology patients.
Keywords: pharmacology, cell biology, therapeutics, cancer, silibinin, Silybin
Anti-Cancer Agents in Medicinal Chemistry
Title: Silibinin – A Promising New Treatment for Cancer
Volume: 10 Issue: 3
Author(s): Catherine Wing Ying Cheung, Norma Gibbons, David Wayne Johnson and David Lawrence Nicol
Affiliation:
Keywords: pharmacology, cell biology, therapeutics, cancer, silibinin, Silybin
Abstract: Silymarin and its major constituent, Silibinin, are extracts from the medicinal plant Silybum marianum (milk thistle) and have traditionally been used for the treatment of liver diseases. Recently, these orally active, flavonoid agents have also been shown to exert significant anti-neoplastic effects in a variety of in vitro and in vivo cancer models, including skin, breast, lung, colon, bladder, prostate and kidney carcinomas. The aim of the present review is to examine the pharmacokinetics, mechanisms, effectiveness and adverse effects of silibinins anti-cancer actions reported to date in pre-clinical and clinical trials. The review will also discuss the results of current research efforts seeking to determine the extent to which the effectiveness of silibinin as an adjunct cancer treatment is influenced by such factors as histologic subtype, hormonal status, stromal interactions and drug metabolising gene polymorphisms. The results of these studies may help to more precisely target and dose silibinin therapy to optimise clinical outcomes for oncology patients.
Export Options
About this article
Cite this article as:
Wing Ying Cheung Catherine, Gibbons Norma, Wayne Johnson David and Lawrence Nicol David, Silibinin – A Promising New Treatment for Cancer, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (3) . https://dx.doi.org/10.2174/1871520611009030186
DOI https://dx.doi.org/10.2174/1871520611009030186 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Designing Novel Molecules for Anti-Cancer Enzyme Modulation: A Mechanistic and Therapeutic Perspective
The deficiencies or hyper functions of enzymes cause a number of diseases. Enzyme inhibition is an important area of pharmaceutical research since studies in this field have already led to the discovery of wide variety of drugs useful in a number of diseases. Specific inhibitors interact with enzymes and block ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Heterocyclic Systems: Bridging Chemistry and Biology in Cancer Therapy
The thematic issue, "Heterocyclic Systems: Bridging Chemistry and Biology in Cancer Therapy," explores the critical role of heterocyclic compounds in advancing the frontiers of cancer treatment. Heterocycles serve as fundamental building blocks in medicinal chemistry due to their structural diversity and ability to interact with biological targets. This issue aims ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Narrative Testimony and Characteristics of Rottlerin for the Treatment of
Various Kinds of Cancer
Current Cancer Therapy Reviews Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Magnetic and Gold-Coated Magnetic Iron Oxide Nanoparticles as Detection Tools: Preparation, Characterization, and Biosensing Applications
Current Nanoscience The Health-promoting Potential of Edible Mushroom Proteins
Current Pharmaceutical Design Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Thermodynamic and Kinetic Aspects Involved in the Development of Nanocarriers and Drug Delivery Systems Based on Cationic Biopolymers
Current Pharmaceutical Design Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis
Current Pharmaceutical Design Honey, Health and Longevity
Current Aging Science The Optimal Diagnosis of Urothelial Carcinoma of the Bladder
Current Cancer Therapy Reviews NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Systemic Treatment of Advanced Biliary Tract Carcinoma: Emerging Roles of Targeted Therapy and Molecular Profiling
Clinical Cancer Drugs Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism Antimicrobial Photosensitizers: Drug Discovery Under the Spotlight
Current Medicinal Chemistry Medicinal Chemistry of P2X Receptors: Allosteric Modulators
Current Medicinal Chemistry Single Chemical Entity Legal Highs: Assessing the Risk for Long Term Harm
Current Drug Abuse Reviews Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design Alternative Splicing and Tumor Progression
Current Genomics Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science